The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Updates on BTK inhibitors for CLL at EHA 2021
Andrea Visentin, MD, PhD, University of Padua, Padova, Italy, discusses exciting updates on the BTK inhibitors acalabrutinib, zanubrutinib and ibrutinib, which will be presented at the virtual European Hematology Association (EHA) Congress 2021. In particular, Dr Visentin highlights updates on the ELEVATE CLL TN trial (NCT02475681), the ELEVATE CLL R/R trial (NCT02477696) and the ALPINE trial (NCT03734016).
Disclosures
Andrea Visentin, MD, PhD, has participated in consultancy work for Gilead, Italffarmaco, Janssen, and Takeda; is a member of the scientific boards of Janssen, Abbvie, CLS Behring; and has participated in speaker’s bureaus for Janssen, Abbvie, AstraZeneca.
